Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.
Nagane M, Ichimura K, Onuki R, Narushima D, Honda-Kitahara M, Satomi K, Tomiyama A, Arai Y, Shibata T, Narita Y, Uzuka T, Nakamura H, Nakada M, Arakawa Y, Ohnishi T, Mukasa A, Tanaka S, Wakabayashi T, Aoki T, Aoki S, Shibui S, Matsutani M, Ishizawa K, Yokoo H, Suzuki H, Morita S, Kato M, Nishikawa R. Nagane M, et al. Among authors: onuki r. Cancers (Basel). 2022 Nov 10;14(22):5522. doi: 10.3390/cancers14225522. Cancers (Basel). 2022. PMID: 36428615 Free PMC article.
Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma.
Kurashina R, Ando K, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y. Kurashina R, et al. Among authors: onuki r. Cancer Diagn Progn. 2023 Mar 3;3(2):230-235. doi: 10.21873/cdp.10206. eCollection 2023 Mar-Apr. Cancer Diagn Progn. 2023. PMID: 36875313 Free PMC article.
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y. Ando K, et al. Among authors: onuki r. Biochem Biophys Res Commun. 2023 Oct 8;676:165-170. doi: 10.1016/j.bbrc.2023.07.054. Epub 2023 Jul 26. Biochem Biophys Res Commun. 2023. PMID: 37517219 Free article.
The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.
Izawa N, Shiokawa H, Onuki R, Hamaji K, Morikawa K, Saji H, Ohashi H, Kasugai S, Hayakawa N, Ohara T, Sunakawa Y. Izawa N, et al. Among authors: onuki r. ESMO Open. 2022 Apr;7(2):100415. doi: 10.1016/j.esmoop.2022.100415. Epub 2022 Mar 2. ESMO Open. 2022. PMID: 35247869 Free PMC article.
Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1.
Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, Toh Y, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y. Oshima K, et al. Among authors: onuki r. Cancer Sci. 2022 Mar;113(3):1018-1027. doi: 10.1111/cas.15251. Epub 2022 Jan 10. Cancer Sci. 2022. PMID: 34962019 Free PMC article. Clinical Trial.
Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment.
Mizukami T, Hamaji K, Onuki R, Yokomizo A, Nagashima Y, Takeda H, Umemoto K, Doi A, Arai H, Hirakawa M, Horie Y, Izawa N, Ogura T, Tsuda T, Sunakawa Y, Shibata M, Tanaka T, Mikami S, Nakajima TE. Mizukami T, et al. Among authors: onuki r. Nutr Cancer. 2022;74(2):539-545. doi: 10.1080/01635581.2021.1902542. Epub 2021 Mar 23. Nutr Cancer. 2022. PMID: 33754895
35 results